The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: A systematic review and meta-analysis of the literature

Human Reproduction Update

Volumn 20, Issue 4, 2014, Pages 560-570

  Iliodromiti, Stamatina ^a   Kelsey, Thomas W ^b   Wu, Olivia ^a   Anderson, Richard A ^c   Nelson, Scott M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Anti M llerian hormone; Diagnostic odds ratio; Hierarchical summary receiver operator characteristic curve; IVF; Live birth

Indexed keywords

MUELLERIAN INHIBITING FACTOR;

AREA UNDER THE CURVE; ARTICLE; CHECKLIST; COCHRANE LIBRARY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EMBASE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; MEDLINE; META ANALYSIS; OVARIAN RESERVE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ANTI-MÜLLERIAN HORMONE; DIAGNOSTIC ODDS RATIO; HIERARCHICAL SUMMARY RECEIVER OPERATOR CHARACTERISTIC CURVE; IVF; LIVE BIRTH;

AGE FACTORS; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; EPIDEMIOLOGIC METHODS; FEMALE; FERTILIZATION IN VITRO; HUMANS; LIVE BIRTH; OVARY;

EID: 84899455502     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmu003     Document Type: Article

References (67)

1. Anckaert E, Smitz J, Schiettecatte J, Klein BM, Arce JC. The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments. Hum Reprod 2012; 27:1829-1839.
2. Arce JC, La Marca A, Mirner Klein B, Nyboe Andersen A, Fleming R. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013;99:1644-1653.
3. Brodin T, Hadziosmanovic N, Berglund L, Olovsson M, Holte J. Antimüllerian hormone levels are strongly associated with live-birth rates after assisted reproduction. J Clin Endocrinol Metab 2013;98:1107-1114.
4. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic reviewof tests predicting ovarian reserve and IVFoutcome. HumReprod Update 2006;12:685-718.
5. Broer SL, Mol BWJ, Hendriks D, Broekmans FJM. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009;91:705-714.
6. Broer SL, Dolleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJM. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 2011;17:46-54.
7. Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, Eijkemans MJC, Mol BWJ, Broekmans FJM. Import Study Group. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013;19:26-36.
8. Cochrane Handbook for DTA reviews. 2011. http://srdta. cochrane. org/ handbook-dta-reviews.
9. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882-893.
10. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 2006;21:2022-2026.
11. Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003; 29:1043-1051.
12. Friden B, Sjoblom P, Menezes J. Using anti-Mullerian hormone to identify a good prognosis group in women of advanced reproductive age. Aust N Z J Obstet Gynaecol 2011;51:411-415.
13. Gatsonis C, Paliwal P. Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer. AJR Am J Roentgenol 2006;187:271-281.
14. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129-1135.
15. Gleicher N, Weghofer A, Barad DH. Anti-Mullerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril 2010;94:2824-2827.
16. Grzegorczyk-Martin V, Khrouf M, Bringer-Deutsch S, Mayenga JM, Kulski O, Cohen-Bacrie P, Benaim JL, Belaisch-Allart J. Pronostic en fécondation in vitro des patientes ayant une AMH basse et une FSH normale. Gynécol Obstét Fertil 2012; 40:411-418.
17. Guerif F, Lemseffer M, Couet ML, Gervereau O, Ract V, Royere D. Serum antimullerian hormone is not predictive of oocyte quality in vitro fertilization. Ann Endocrinol 2009;70:230-234.
18. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril 2011;95:170-175.
19. Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics (Oxford, England) 2007; 8:239-251.
20. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006;91:4057-4063.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
22. Honnma H, Baba T, Sasaki M, Hashiba Y, Oguri H, Fukunaga T, Endo T, Asada Y. Serum anti-Mullerian hormone levels affect the rate of ongoing pregnancy after in vitro fertilization. Reprod Sci 2013;20:51-59.
23. Irez T, Ocal P, Guralp O, Cetin M, Aydogan B, Sahmay S. Different serum anti-Mullerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes. Arch Gynecol Obstet 2011;284:1295-1301.
24. Irwig L, Tosteson AN, Gatsonis C, Lau J, Colditz G, Chalmers TC, Mosteller F. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 1994; 120:667-676.
25. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based MedicineWorking Group. JAMA 1994; 271:703-707.
26. Jeppesen JV, Anderson RA, KelseyTW, Christiansen SL, Kristensen SG, Jayaprakasan K, Raine-Fenning N, Campbell BK, Yding Andersen C. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod 2013;19:519-527.
27. Kedem-Dickman A, Maman E, Yung Y, Yerushalmi GM, Hemi R, Hanochi M, Dor J, Hourvitz A. Anti-Mullerian hormone is highly expressed and secreted from cumulus granulosa cells of stimulated preovulatory immature and atretic oocytes. Reprod Biomed Online 2012;24:540-546.
28. Khader A, Lloyd SM, McConnachie A, Fleming R, Grisendi V, La Marca A, Nelson SM. External validation of anti-Mullerian hormone based prediction of live birth in assisted conception. J Ovarian Res 2013;6:3.
29. Khan KS, Dinnes J, Kleijnen J. Systematic reviewsto evaluate diagnostic tests. Eur J Obstet Gynecol Reprod Biol 2001;95:6-11.
30. Kline JK, Kinney AM, Levin B, Kelly AC, Ferin M, Warburton D. Trisomic pregnancy and elevated FSH: implications for the oocyte pool hypothesis. Hum Reprod 2011; 26:1537-1550.
31. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010;16:113-130.
32. La Marca A, Nelson SM, Sighinolfi G, Manno M, Baraldi E, Roli L, Xella S, Marsella T, Tagliasacchi D, D'Amico R et al. Anti-Mullerian hormone-based prediction model for a live birth in assisted reproduction. Reprod Biomed Online 2011;22:341-349.
33. Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS. Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol 2009;7:100.
34. Li HW, Lee VC, Lau EY, Yeung WS, Ho PC, Ng EH. Role of baseline antral follicle count and anti-mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis. PLoS One 2013;8:e61095.
35. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
36. Lie Fong S, Baart EB, Martini E, Schipper I, Visser JA, Themmen AP, de Jong FH, Fauser BJ, Laven JS. Anti-Mullerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reprod Biomed Online 2008;16:664-670.
37. Lin WQ, Yao LN, Zhang DX, Zhang W, Yang XJ, Yu R. The predictive value of anti-mullerian hormone on embryo quality, blastocyst development, and pregnancy rate following in vitro fertilization-embryo transfer (IVF-ET). J Assist Reprod Genet 2013;30:649-655.
38. Lukaszuk K, Kunicki M, Liss J, Lukaszuk M, Jakiel G. Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization. Eur J Obstet Gynecol Reprod Biol 2013;168:173-177.
39. Majumder K, Gelbaya TA, Laing I, Nardo LG. The use of anti-Mullerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol 2010;150:166-170.
40. Mashiach R, Amit A, Hasson J, Amzalzg S, Almog B, Ben-Yosef D, Lessing JB, Limor R, Azem F. Follicular fluid levels of anti-Mullerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome. Fertil Steril 2010;93:2299-2302.
41. Merhi Z, Zapantis A, Berger DS, Jindal SK. Determining an anti-mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve. J Assist Reprod Genet 2013;30:1361-1365.
42. Mutlu MF, Erdem M, Erdem A, Yildiz S, Mutlu I, Arisoy O, Oktem M. Antral follicle count determines poor ovarian response better than anti-mullerian hormone but age is the only predictor for live birth in in vitro fertilization cycles. J Assist Reprod Genet 2013; 30:657-665.
43. Nelson SM, La Marca A. The journey from the old to the newAMHassay: how to avoid getting lost in the values. Reprod Biomed Online 2011;23:411-420.
44. Nelson SM, Lawlor DA. Predicting live birth, preterm delivery, and low birth weight in infants born from in vitro fertilisation: a prospective study of 144018 treatment cycles. PLoS Med 2011;8:e1000386.
45. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod 2007;22:2414-2421.
46. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, Ambrose P, Fleming R. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867-875.
47. Nelson SM, Iliodromiti S, Fleming R, Anderson R, McConnachie A, Messow CM. Reference range for the antimullerian hormone Generation II assay: a population study of 10, 984 women, with comparison to the established Diagnostics Systems Laboratory nomogram. Fertil Steril 2013a. doi:pii: S0015-0282(13)03167-1.
48. Nelson SM, Telfer EE, Anderson RA. The ageing ovary and uterus: new biological insights. Hum Reprod Update 2013b;19:67-83.
49. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ 2000;320:1708-1712.
50. Oudendijk JF, Yarde F, Eijkemans MJ, Broekmans FJ, Broer SL. The poor responder in IVF: is the prognosis always poor? A systematic review. Hum Reprod Update 2012; 18:1-11.
51. Plante BJ, Beamon C, Schmitt CL, Moldenhauer JS, Steiner AZ. Maternal antimullerian hormone levels do not predict fetal aneuploidy. J Assist Reprod Genet 2010; 27:409-414.
52. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-990.
53. Riggs R, Kimble T, Oehninger S, Bocca S, Zhao Y, Leader B, Stadtmauer L. Anti-Mullerian hormone serum levels predict response to controlled ovarian hyperstimulation but not embryo quality or pregnancy outcome in oocyte donation. Fertil Steril 2011;95:410-412.
54. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001;20:2865-2884.
55. Salmon NA, Handyside AH, Joyce IM. Oocyte regulation of anti-Mullerian hormone expression in granulosa cells during ovarian follicle development in mice. Dev Biol 2004;266:201-208.
56. Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM, Braat DD. Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril 2007; 87:223-226.
57. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
58. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod 2011;26:1768-1774.
59. TakwoingiY, Deeks JJ. MetaDAS. ASAS macro for meta-analysis of diagnostic accuracy studies. User Guide Version 1. 3, 2010. http://srdta. cochrane. org/
60. van Loendersloot LL, vanWely M, Limpens J, Bossuyt PM, Repping S, van der Veen F. Predictive factors in in vitro fertilization (IVF): a systematic review and meta-analysis. Hum Reprod Update 2010;16:577-589.
61. van Loendersloot L, Repping S, Bossuyt PMM, van der Veen F, vanWely M. Prediction models in in vitro fertilization; where are we? J Advanc Res 2013. doi:10. 1016/ j. jare. 2013. 05. 002.
62. van Rooij IAJ, Broekmans FJM, Hunault CC, Scheffer GJ, Eijkemans MJC, de Jong FH, Themmen APN, te Velde ER. Use of ovarian reserve tests for the prediction of ongoing pregnancy in couples with unexplained or mild male infertility. Reprod Biomed Online 2006;12:182-190.
63. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One 2010;5:e8772.
64. Wang JG, Douglas NC, Nakhuda GS, Choi JM, Park SJ, Thornton MH, Guarnaccia MM, Sauer MV. The association between anti-Mullerian hormone and IVF pregnancy outcomes is influenced by age. Reprod Biomed Online 2010; 21:757-761.
65. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, Kramer P, Fauser BC, Themmen AP. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77-83.
66. Weghofer A, Dietrich W, Barad DH, Gleicher N. Live birth chances in women with extremely low-serum anti-Mullerian hormone levels. Hum Reprod 2011; 26:1905-1909.
67. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-536.